Clinical Trial Update: Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of finerenone in participants with heart failure and left ventricular ejection fraction ≥40% has completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Kerendia (finerenone)

Snippet

Sponsor: Bayer | Conditions: Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2025-08-26